This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Phillip D. Carter
Head of U.S. Market Access at Orchard Therapeutics


Phillip D. Carter, Head of U.S. Market Access at Orchard Therapeutics, leads the U.S. team responsible for aligning the needs of payers, patients, and other stakeholders to help ensure Orchard’s potentially curative ex vivo autologous hematopoietic stem cell (HSC) gene therapies can be accessed by those who need them.  Driven by a personal passion for improving the lives of patients, Mr. Carter has dedicated more than 20 years of his career to bringing innovative medicines to market, including multiple therapies for rare and ultra-rare conditions.  Mr. Carter serves as a collaborative partner and committee member to multiple organizations – including the Financing & Reimbursement of Cures in the U.S. (FoCUS) Project for MIT’s New Drug Development Paradigms (NEWDIGS) program, as well as the Policy, Access and Reimbursement Committee (PARC) at Biotechnology Innovation Organization (BIO).

Agenda Sessions

  • PANEL: Reimbursement Models for Novel Therapies